23. Modulation of Innate Immunity with the Anti CTLA4 Antibody Ipilimumab (Ipi) in Measles Virotherapy for Glioblastoma

Glioblastoma (GBM) is one of the deadliest malignancies with a median survival of 12-16 months. This leaves an urgent need for improved therapies. Use of the measles virus Edmonston vaccine strain lineage for GBM virotherapy represents a promising direction due to an excellent safety record and demonstrated pre-clinical efficacy in multiple patient derived orthotopic models. Previous reports of virotherapy combined with the immune modulatory drug, cyclophosphamide (CPA), have demonstrated increased efficacy in preclinical models in part through CPA’s ability to inhibit the monocyte driven innate immune response against oncolytic viruses. CPA, however, is an alkylating agent that indiscriminately affects many organ systems during therapy. We therefore sought to identify an agent that could more specifically target the innate immune response and in particular the monocyte response to virotherapy. Human …